[Radiotherapy and targeted therapies in head and neck carcinomas and NSCLC].
Targeted therapies are at this moment the subject of an intensive research program in head and neck carcinomas and in NSCLC. Their combination with radiotherapy is promising. The studied targets are mostly the EGF receptor and the angiogenesis, with drugs such as cetuximab or bevacizumab. The first clinical results are now available, mostly in head and neck carcinomas. The radiosensitivity is increased, resulting in better survival results, however with a good tolerance profile. Numbers of clinical trials are active now to confirm these results. Particularly, their addition to the reference treatments that are chemo-radiotherapy is studied. The first clinical results will be detailed, as well as their biological explanation.
Département de radiothérapie, institut Gustave-Roussy, 94800 Villejuif, France. abruna@oncorad.courlancy.fr
A
A
Bruna
J
J
Bourhis
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy / Q000532:radiotherapy; D000068818:Cetuximab; D003131:Combined Modality Therapy / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006258:Head and Neck Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000532:radiotherapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011836:Radiation Tolerance
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D066246:ErbB Receptors; D000068818:Cetuximab